Login to Your Account



Idenix Stock Plummets 47% on Negative HCV Drug Data

By Catherine Hollingsworth


Wednesday, September 8, 2010
Shares in Idenix Pharmaceuticals Inc. sank 47 percent as the FDA placed a clinical hold on studies of IDX184 and IDX320 for hepatitis C virus due to elevated liver enzymes in three healthy volunteers. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription